The results of cerebrospinal fluid (CSF) 
With the introduction of the use of the Ommaya device in the treatment of leptomeningeal metastasis, the ventricular CSF became readily available for analysis of the biochemical markers. In this study we analysed the results of the markers carcinoembryonic antigen (CEA), f,-glucuronidase, lactate dehydrogenase (LDH), fl2-microglobulin and of routine glucose and total protein, during therapy in relation to the findings of lumbar and ventricular CSF cytology.
Methods
Twenty five patients were referred to the Netherlands Cancer Institute for treatment. The primary site of malignancy, the follow up period and the number of CSF samples for each patient are given in table 1. The diagnosis of leptomeningeal metastasis was confirmed in all cases by a positive CSF cytology.
Three patients were already being treated when this study started. All patients were treated with intraventricular methotrexate (MTX), six patients in combination with cranial radiotherapy. No steroids or other symptomatic treatments were used. None of the patients is still being treated.
Ventricular and lumbar punctures were carried out as part of the diagnostic and treatment procedures but not for the measurements of the markers alone. To obtain ventricular CSF, the Ommaya reservoir was inserted with a 23 gauge butterfly needle. Three ml of CSF, which had passed through the reservoir and tubing was withdrawn and discarded. An additional 7 ml was then removed from the ventricle for the purpose of sampling. When clinically necessary, a total of 10 ml CSF was also removed by lumbar puncture one hour after the sampling from the Ommaya reservoir.
For cytological examination, slides were prepared by the cytocentrifuge technique (Shandon Elliot cytospin). The slides were airdried, fixed in methanol and routinely stained with Giemsa.
After centrifuging the samples, glucose, protein and LDH were determined immediately. Protein was measured using an adaptation on the ACA of the trichloroacetic acid procedure described by Meulemans."1 /32-microglobulin (standardised to age) 065-2-20 mg/l; CEA <4 pg/l. In a previous study'7 stepwise linear discriminant analysis (LDA) was carried out to classify the lumbar CSF samples into two categories: leptomeningeal spread present or absent. The discriminant functions for this analysis were generated from observations on a total of 265 patients, with metastatic and non metastatic diseases. In this study, the patients were classified by evaluating the scores obtained by the discriminant score functions from the previous study and assigning the patient to the group whose discriminant score function had the maximum score, that is, leptomeningeal spread present or absent. The ventricular samples from each patient were divided into two categories, positive and In lumbar CSF values for protein, LDH, ,Bglucuronidase, /2-microglobulin, and CEA were higher than those measured in the ventricular CSF. In contrast, ventricular CSF showed the highest glucose values (table 2) .
By an allocation procedure, based on LDA of the combination of patient's age and the marker values for ,B-glucuronidase and f2-microglobulin in lumbar CSF, it was possible to allocate the lumbar CSF samples in two categories, that is, meningeal spread present or absent. Table 3 presents the results for 18 samples obtained at diagnostic puncture. In 32 lumbar samples, obtained during follow up (table 4) a statistically significant difference was found (McNemar P = 0 036) between the probability to be positive by LDA classification and cytology. In three of the 12 samples, with positive markers and negative cytology, there was evidence of infectious complications. By omitting these samples from the statistical circuit in the ACA, which produces only results which are multiples of two, for example, 0, 2, 4, 6, etc U/1.
Discussion
In evaluating the diagnostic value of CSF tumour markers in patients treated for leptomeningeal metastasis, there are several serious problems that need to be confronted. These are connected with the site of CSF puncture, the effects of therapy on blood/CSF barrier and with estimating reference values, particularly in ventricular CSF. During the investigations leading to the diagnosis of leptomeningeal metastasis, it is usually lumbar CSF which is submitted to the clinical and cytological laboratory. During therapy, and after the installation of an Ommaya device, it is ventricular CSF which is usually submitted.
The composition of CSF can differ considerably between different CSF sources, such as the Ommaya reservoir or the lumbar space, even in the absence of an extra dural block. '9 Reference values should therefore be estimated for lumbar and for ventricular CSF. For lumbar CSF, the methods for obtaining our reference values are described elsewhere.' For ventricular CSF, the methods used for lumbar CSF cannot be used, mainly because of problems obtaining ventricular CSF for reference purposes. As only ventricular CSF from patients treated for their leptomeningeal metastases is submitted to our laboratory, we estimated the ventricular reference values with Neuman's method '8 In conclusion, when interpreting CSF tumour markers during therapy they should be compared with test results with a reference range estimated for a specific region of the neuraxis, and that bacterial or fungal infections in particular should be excluded from the diagnosis by careful bacteriological examination of the CSF. During therapy the measurements of CSF tumour markers are not superior to CSF cytology in samples with elevated cell counts. Perhaps CSF tumour markers are most useful in samples with low cell counts, although this subject merits further serious attention.
